This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

29 May 2014

Aesica and Colorcon Host Workshop on Continuous Processing Together with Pharmaceutical Industry Companies

Two leading global companies, pharmaceutical contract development and manufacturing organisation (CDMO) Aesica and speciality excipient and coating company, Colorcon, are today co-hosting a ground breaking workshop at the Royal College of Physicians in London. This key industry event is focused on major advances and challenges in the emerging field of continuous processing. The workshop will bring together leading experts from the pharmaceutical sector to discuss this potentially transformational approach and explore its implications for the development and manufacture of solid oral dosage forms. 


In addition to Aesica and Colorcon, representatives from AstraZeneca, Pfizer, GSK, GEA Process Engineering and Vertex Pharmaceuticals will speak on a multitude of continuous processing related topics. The themes range from

• Multipurpose approaches for solid oral dose manufacture, including both rapid development paradigms and continuous process design

• The speed of the process – from powder to a coated tablet in less than one hour

• Recent advances in continuous film coating technologies

• Industrial challenges and opportunities in continuous processing for tablet manufacturing

• Continuous drug product manufacturing for breakthrough therapies.


Jeremy Drummond, Sales Director, Finished Dose at Aesica commented: “We are delighted to be at the joint forefront of bringing together key industry experts in continuous processing, from across the pharmaceutical industry sector, in what is designed to be a highly informative forum for discussion, understanding and the sharing of knowledge. The workshop will provide authoritative and stimulating insights from within the pharmaceutical industry to aid and assist the drawing up of the very best framework that will oversee this new, growing and exciting field.”  


He added: “Continuous processing is fast emerging as a real asset to solid oral dosage manufacture. Consequently, we are especially pleased that this event, which we are co-hosting with Colorcon, has brought together such a wide range of specialists from leading pharmaceuticals companies, as well as our technical centers. This is set to ensure that it will be a very informative affair for all concerned.”


Dr Ali Rajabi-Siahboomi, VP & Chief Scientific Officer at Colorcon shared his insight on the event: “As Quality by Design (QbD) initiatives are progressing in the pharmaceutical industry, continuous processing and manufacturing of drug products are becoming more acceptable and realistic. This highly interactive workshop provides unique opportunities for a timely and open dialogue across industry stakeholders. Our goal is to provide attendees with a forum to discuss practical applications that aid in the development and manufacture of solid oral dosage forms. The event presents a unique opportunity to discuss real and perceived hurdles for successful implementation and create clarity on the benefits of continuous processing for pharmaceuticals.”

Related News